Camrelizumab Priced at RMB 19,800 per Vial, Becomes Most Expensive Domestic PD-1 Inhibitor

VCBeat has learned that Suzhou Shengdiya Biopharmaceutical Co., Ltd., a subsidiary of Hengrui Medicine, has announced the pricing for its PD-1 monoclonal antibody product, Airuituo (generic name: camrelizumab). The retail price of Airuituo is set at RMB 19,800 per vial, with a specification of 200 mg. This retail price is higher than those of Junshi Biosciences’ Tuoyi and Innovent Biologics’ Tyvyt. As the specific dosage and administration regimen have not yet been disclosed, it is currently not possible to compare the treatment costs of Airuituo with those of other similar products.

Regarding the current approval of camrelizumab, we have alreadyCamrelizumab is set to launch, marking the entry of China’s PD-1 market competition into its second phase.The article reported on this.